Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Pannecouque

Showing results (1-10 of 426) with videos related to

Pageof 43
Sort By:
Current Opinion in HIV and AIDS|April 18, 2009
HIV-1 Rev function as target for antiretroviral drug developmentDirk Daelemans, Christophe Pannecouque
Chemistry & Biodiversity|October 20, 2012
Synthesis, and in vitro enzymatic and antiviral evaluation of d4T polyphosphate derivatives as chain terminatorsShiqiong Yang, Christophe Pannecouque, Piet Herdewijn
Chemical Biology & Drug Design|August 21, 2013
Discovery of HIV-1 integrase inhibitors: pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluationHardik Bhatt, Paresh Patel, Christophe Pannecouque
Nature Protocols|March 8, 2008
Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years laterChristophe Pannecouque, Dirk Daelemans, Erik De Clercq
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|June 15, 2007
Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct waysKristel Van Laethem, Christophe Pannecouque, Anne-Mieke Vandamme
Nature Protocols|June 4, 2011
A time-of-drug addition approach to target identification of antiviral compoundsDirk Daelemans, Rudi Pauwels, Erik De Clercq, et al.
Biochemical Pharmacology|January 28, 2006
Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-kappaB bindingMiguel Stevens, Christophe Pannecouque, Erik De Clercq, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2014
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agentsKishore Lingam Gangadhara, Eveline Lescrinier, Christophe Pannecouque, et al.
Acta Pharmaceutica Sinica. B|July 10, 2020
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty yearsChunlin Zhuang, Christophe Pannecouque, Erik De Clercq, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV actionMiguel Stevens, Christophe Pannecouque, Erik De Clercq, et al.
Pageof 43

Showing results (1-10 of 426) with videos related to

Sort By:
Pageof 43
Current Opinion in HIV and AIDS|April 18, 2009
HIV-1 Rev function as target for antiretroviral drug developmentDirk Daelemans, Christophe Pannecouque
Chemistry & Biodiversity|October 20, 2012
Synthesis, and in vitro enzymatic and antiviral evaluation of d4T polyphosphate derivatives as chain terminatorsShiqiong Yang, Christophe Pannecouque, Piet Herdewijn
Chemical Biology & Drug Design|August 21, 2013
Discovery of HIV-1 integrase inhibitors: pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluationHardik Bhatt, Paresh Patel, Christophe Pannecouque
Nature Protocols|March 8, 2008
Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years laterChristophe Pannecouque, Dirk Daelemans, Erik De Clercq
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|June 15, 2007
Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct waysKristel Van Laethem, Christophe Pannecouque, Anne-Mieke Vandamme
Nature Protocols|June 4, 2011
A time-of-drug addition approach to target identification of antiviral compoundsDirk Daelemans, Rudi Pauwels, Erik De Clercq, et al.
Biochemical Pharmacology|January 28, 2006
Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-kappaB bindingMiguel Stevens, Christophe Pannecouque, Erik De Clercq, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2014
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agentsKishore Lingam Gangadhara, Eveline Lescrinier, Christophe Pannecouque, et al.
Acta Pharmaceutica Sinica. B|July 10, 2020
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty yearsChunlin Zhuang, Christophe Pannecouque, Erik De Clercq, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV actionMiguel Stevens, Christophe Pannecouque, Erik De Clercq, et al.
Pageof 43